A globally pioneering high-efficiency protein-expression system that enables high-yield, high-quality production of complex proteins, providing critical support for vaccine R&D.

Wantai BioPharm’s E. coli antigen platform is one of its core strengths; it owns proprietary intellectual property for a prokaryotic VLP (virus-like particle) vaccine technology system based on E. coli.

The platform overcomes the long-standing challenge of assembling protein particles in a prokaryotic system. It retains all the benefits of low cost, high efficiency, easy scale-up and safety, and is readily adaptable to vaccines against a wide range of pathogens.

By leveraging the strong immunogenicity and safety profile of VLP vaccines, the platform has already powered the launch of the hepatitis E vaccine, the nine-valent HPV vaccine and the bivalent HPV vaccine, and is being extended to all HPV types as well as to HBV and rotavirus vaccines.

A non-invasive nasal spray replaces needle injection, eliminating pain and trauma and markedly improving accessibility and compliance. This approach is ideal for mass-immunization campaigns and for pediatric populations.

Delivery directly to the nasal mucosa activates the respiratory mucosal immune system, establishing a protective barrier at the very site where viruses first invade, thereby reducing both infection and transmission risk.

A world-leading production line for live-attenuated intranasal vaccines has been established, enabling rapid scale-up to meet the demands of emerging outbreaks.

Leveraging the dual advantages of mucosal and systemic immunity, the platform has already produced COVID-19 vaccines and is being extended to vaccines against influenza, respiratory syncytial virus (RSV), and other respiratory pathogens.